Human monoclonal antibodies that neutralize pandemic gii.4 noroviruses
AssigneeVanderbilt University
InventorJames E. CROWE, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof.
Claims29
A method of detecting a norovirus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) detecting norovirus in said sample by binding of said antibody or antibody fragment to a norovirus antigen in said sample.
2-12. (canceled)
A method of treating a subject infected with norovirus, or reducing the likelihood of infection of a subject at risk of contracting norovirus, comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
A monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
27-35. (canceled)
A hybridoma or engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
37-46. (canceled)
A vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
48-56. (canceled)
58-60. (canceled)
A method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with norovirus comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
62-75. (canceled)
A method of determining the antigenic integrity, correct conformation and/or correct sequence of a norovirus antigen comprising:
- (a) contacting a sample comprising said antigen with a first antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) determining antigenic integrity, correct conformation and/or correct sequence of said antigen by detectable binding of said first antibody or antibody fragment to said antigen.
77-96. (canceled)
A human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, wherein said antibody or antibody fragment binds to norovirus capsid protein P domain and/or S domain.
98-101. (canceled)
Dependencies are inferred from the claim text.